Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Atherosclerosis | 67 | 2024 | 935 | 9.100 |
Why?
|
Cardiovascular Diseases | 65 | 2024 | 2195 | 8.290 |
Why?
|
Troponin T | 42 | 2024 | 261 | 5.490 |
Why?
|
Carotid Intima-Media Thickness | 20 | 2023 | 79 | 4.610 |
Why?
|
Heart Failure | 46 | 2024 | 2516 | 4.460 |
Why?
|
Coronary Artery Disease | 29 | 2024 | 1011 | 4.110 |
Why?
|
Natriuretic Peptide, Brain | 27 | 2024 | 343 | 4.040 |
Why?
|
Plaque, Atherosclerotic | 16 | 2023 | 160 | 3.480 |
Why?
|
Coronary Disease | 24 | 2023 | 764 | 3.480 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 32 | 2024 | 849 | 3.390 |
Why?
|
Biomarkers | 82 | 2024 | 5047 | 3.020 |
Why?
|
Carotid Artery Diseases | 12 | 2020 | 196 | 2.900 |
Why?
|
Risk Assessment | 59 | 2024 | 6869 | 2.830 |
Why?
|
Hypertension | 19 | 2024 | 1503 | 2.820 |
Why?
|
Cholesterol, LDL | 23 | 2024 | 565 | 2.710 |
Why?
|
Risk Factors | 123 | 2024 | 17523 | 2.540 |
Why?
|
Diabetes Mellitus | 18 | 2024 | 1054 | 2.430 |
Why?
|
Dyslipidemias | 10 | 2021 | 235 | 2.350 |
Why?
|
Peptide Fragments | 23 | 2024 | 1271 | 2.290 |
Why?
|
Myocardial Infarction | 19 | 2024 | 1374 | 2.210 |
Why?
|
Proprotein Convertase 9 | 7 | 2024 | 69 | 2.170 |
Why?
|
Vascular Stiffness | 7 | 2022 | 77 | 2.120 |
Why?
|
Hyperlipoproteinemia Type II | 5 | 2021 | 78 | 2.100 |
Why?
|
Carotid Arteries | 7 | 2022 | 240 | 2.040 |
Why?
|
Blood Pressure | 16 | 2024 | 1467 | 2.020 |
Why?
|
Peripheral Arterial Disease | 15 | 2023 | 267 | 1.940 |
Why?
|
Anticholesteremic Agents | 6 | 2024 | 256 | 1.620 |
Why?
|
Cholesterol | 13 | 2021 | 658 | 1.560 |
Why?
|
Humans | 262 | 2024 | 261506 | 1.420 |
Why?
|
C-Reactive Protein | 18 | 2023 | 527 | 1.400 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 9 | 2019 | 98 | 1.380 |
Why?
|
Stroke | 14 | 2023 | 1144 | 1.320 |
Why?
|
Acute Coronary Syndrome | 6 | 2021 | 259 | 1.310 |
Why?
|
Carotid Artery, Common | 5 | 2012 | 91 | 1.250 |
Why?
|
Preventive Health Services | 2 | 2018 | 75 | 1.180 |
Why?
|
Galectin 3 | 4 | 2024 | 138 | 1.140 |
Why?
|
Heart Diseases | 5 | 2019 | 732 | 1.110 |
Why?
|
Vascular Calcification | 3 | 2024 | 50 | 1.070 |
Why?
|
Obesity | 16 | 2023 | 2884 | 1.040 |
Why?
|
Hypolipidemic Agents | 6 | 2021 | 190 | 1.020 |
Why?
|
Carotid Artery, Internal | 3 | 2015 | 77 | 0.980 |
Why?
|
Male | 150 | 2024 | 123000 | 0.950 |
Why?
|
United States | 60 | 2024 | 15433 | 0.950 |
Why?
|
Echocardiography | 6 | 2023 | 1182 | 0.940 |
Why?
|
Serine Proteinase Inhibitors | 3 | 2019 | 60 | 0.940 |
Why?
|
Middle Aged | 130 | 2024 | 86204 | 0.940 |
Why?
|
Carotid Stenosis | 5 | 2021 | 176 | 0.920 |
Why?
|
Brain Ischemia | 5 | 2023 | 292 | 0.880 |
Why?
|
Troponin | 4 | 2024 | 92 | 0.860 |
Why?
|
Incidence | 32 | 2021 | 5673 | 0.850 |
Why?
|
Prospective Studies | 46 | 2024 | 12873 | 0.850 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2016 | 592 | 0.850 |
Why?
|
Coronary Vessels | 5 | 2021 | 665 | 0.840 |
Why?
|
Tunica Intima | 3 | 2011 | 117 | 0.830 |
Why?
|
Female | 142 | 2024 | 141928 | 0.800 |
Why?
|
Lipoprotein(a) | 7 | 2022 | 113 | 0.790 |
Why?
|
Dicarboxylic Acids | 1 | 2021 | 33 | 0.790 |
Why?
|
Aged | 99 | 2023 | 70117 | 0.770 |
Why?
|
Ultrasonography | 6 | 2015 | 1863 | 0.770 |
Why?
|
Calcium | 6 | 2024 | 1537 | 0.760 |
Why?
|
Sleep Apnea, Obstructive | 3 | 2023 | 228 | 0.750 |
Why?
|
Chromosomes, Human, Pair 9 | 5 | 2012 | 290 | 0.750 |
Why?
|
Vascular Diseases | 3 | 2022 | 246 | 0.730 |
Why?
|
Cardiology | 8 | 2023 | 530 | 0.720 |
Why?
|
Lipids | 9 | 2023 | 644 | 0.720 |
Why?
|
American Heart Association | 6 | 2023 | 310 | 0.720 |
Why?
|
General Practitioners | 1 | 2019 | 14 | 0.700 |
Why?
|
Platelet Aggregation Inhibitors | 7 | 2021 | 444 | 0.700 |
Why?
|
Body Mass Index | 14 | 2023 | 2203 | 0.690 |
Why?
|
Percutaneous Coronary Intervention | 2 | 2021 | 342 | 0.690 |
Why?
|
Metabolic Syndrome | 5 | 2016 | 353 | 0.690 |
Why?
|
Inflammation | 7 | 2022 | 2522 | 0.690 |
Why?
|
Protein Precursors | 4 | 2021 | 240 | 0.680 |
Why?
|
Practice Guidelines as Topic | 12 | 2019 | 2403 | 0.680 |
Why?
|
Hyperlipidemias | 2 | 2015 | 235 | 0.670 |
Why?
|
Fatty Acids | 1 | 2021 | 448 | 0.640 |
Why?
|
Renal Insufficiency, Chronic | 6 | 2022 | 787 | 0.640 |
Why?
|
Heterozygote | 1 | 2021 | 1020 | 0.640 |
Why?
|
Cognition Disorders | 2 | 2021 | 786 | 0.640 |
Why?
|
Blood Pressure Determination | 2 | 2016 | 109 | 0.630 |
Why?
|
Phospholipases A | 5 | 2014 | 52 | 0.620 |
Why?
|
Education | 1 | 2018 | 112 | 0.620 |
Why?
|
Population Surveillance | 2 | 2021 | 627 | 0.620 |
Why?
|
Fatty Acids, Omega-3 | 3 | 2021 | 83 | 0.590 |
Why?
|
Echocardiography, Three-Dimensional | 2 | 2016 | 66 | 0.590 |
Why?
|
Primary Prevention | 5 | 2021 | 255 | 0.580 |
Why?
|
Atrial Fibrillation | 6 | 2023 | 719 | 0.570 |
Why?
|
Myocardium | 4 | 2019 | 1313 | 0.560 |
Why?
|
Dementia | 1 | 2021 | 453 | 0.560 |
Why?
|
Prognosis | 30 | 2024 | 21713 | 0.550 |
Why?
|
Predictive Value of Tests | 16 | 2019 | 4892 | 0.550 |
Why?
|
Women's Health | 1 | 2017 | 205 | 0.550 |
Why?
|
Antihypertensive Agents | 5 | 2023 | 395 | 0.530 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2023 | 1362 | 0.520 |
Why?
|
Coronary Artery Bypass | 10 | 2013 | 708 | 0.520 |
Why?
|
Postprandial Period | 1 | 2015 | 85 | 0.520 |
Why?
|
Triglycerides | 8 | 2022 | 603 | 0.510 |
Why?
|
Hospitalization | 11 | 2022 | 2083 | 0.510 |
Why?
|
Thrombosis | 1 | 2021 | 781 | 0.510 |
Why?
|
Football | 5 | 2014 | 37 | 0.500 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2015 | 80 | 0.500 |
Why?
|
Cohort Studies | 28 | 2023 | 9244 | 0.500 |
Why?
|
Hypercholesterolemia | 5 | 2021 | 259 | 0.490 |
Why?
|
Health Status Disparities | 1 | 2017 | 291 | 0.490 |
Why?
|
Tunica Media | 2 | 2011 | 22 | 0.490 |
Why?
|
Magnetic Resonance Imaging | 17 | 2023 | 7702 | 0.490 |
Why?
|
Hypoxia | 2 | 2023 | 443 | 0.480 |
Why?
|
Leg | 5 | 2023 | 226 | 0.480 |
Why?
|
Ankle Brachial Index | 6 | 2022 | 34 | 0.480 |
Why?
|
Oligonucleotides | 1 | 2015 | 227 | 0.470 |
Why?
|
Troponin I | 4 | 2024 | 127 | 0.470 |
Why?
|
Oligonucleotides, Antisense | 1 | 2015 | 248 | 0.470 |
Why?
|
Reproducibility of Results | 14 | 2022 | 6009 | 0.470 |
Why?
|
Disease Management | 3 | 2017 | 1052 | 0.470 |
Why?
|
Dietary Fats | 1 | 2015 | 339 | 0.460 |
Why?
|
Time Factors | 24 | 2021 | 12926 | 0.460 |
Why?
|
Imaging, Three-Dimensional | 2 | 2015 | 925 | 0.450 |
Why?
|
Image Enhancement | 1 | 2016 | 561 | 0.440 |
Why?
|
Sleep Apnea Syndromes | 2 | 2023 | 82 | 0.440 |
Why?
|
Pulse Wave Analysis | 4 | 2022 | 45 | 0.430 |
Why?
|
Ultrasonography, Doppler, Pulsed | 1 | 2012 | 17 | 0.430 |
Why?
|
Aspirin | 5 | 2021 | 455 | 0.420 |
Why?
|
Ultrasonography, Doppler | 3 | 2014 | 231 | 0.410 |
Why?
|
Platelet Aggregation | 2 | 2011 | 257 | 0.410 |
Why?
|
Peripheral Vascular Diseases | 3 | 2011 | 136 | 0.410 |
Why?
|
Clinical Competence | 2 | 2019 | 1270 | 0.410 |
Why?
|
Sensitivity and Specificity | 11 | 2019 | 4971 | 0.400 |
Why?
|
Goals | 4 | 2020 | 185 | 0.400 |
Why?
|
Cholesterol, HDL | 4 | 2011 | 341 | 0.400 |
Why?
|
Prediabetic State | 2 | 2024 | 57 | 0.390 |
Why?
|
Vasa Vasorum | 1 | 2010 | 3 | 0.390 |
Why?
|
Purinergic P2Y Receptor Antagonists | 3 | 2021 | 48 | 0.390 |
Why?
|
Retirement | 4 | 2014 | 22 | 0.390 |
Why?
|
Peroxidase | 3 | 2008 | 132 | 0.380 |
Why?
|
Veterans | 5 | 2023 | 1641 | 0.380 |
Why?
|
Elasticity Imaging Techniques | 1 | 2013 | 171 | 0.380 |
Why?
|
Ezetimibe | 5 | 2019 | 101 | 0.370 |
Why?
|
Cardiomyopathies | 4 | 2019 | 610 | 0.360 |
Why?
|
Hypertriglyceridemia | 3 | 2022 | 104 | 0.360 |
Why?
|
Proportional Hazards Models | 16 | 2022 | 4988 | 0.350 |
Why?
|
Polymorphism, Single Nucleotide | 13 | 2013 | 4549 | 0.350 |
Why?
|
HIV Infections | 2 | 2020 | 2134 | 0.350 |
Why?
|
Health Status Indicators | 1 | 2010 | 224 | 0.350 |
Why?
|
Risk Reduction Behavior | 3 | 2020 | 227 | 0.330 |
Why?
|
Platelet Activation | 1 | 2009 | 116 | 0.330 |
Why?
|
Secondary Prevention | 2 | 2021 | 329 | 0.330 |
Why?
|
Healthy Lifestyle | 2 | 2020 | 44 | 0.330 |
Why?
|
Hypertrophy, Left Ventricular | 3 | 2022 | 112 | 0.330 |
Why?
|
Life Expectancy | 1 | 2009 | 129 | 0.330 |
Why?
|
Prevalence | 11 | 2021 | 3260 | 0.320 |
Why?
|
Adult | 39 | 2023 | 77950 | 0.310 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2008 | 58 | 0.310 |
Why?
|
Follow-Up Studies | 22 | 2021 | 14889 | 0.310 |
Why?
|
Exercise | 4 | 2021 | 1183 | 0.310 |
Why?
|
Treatment Outcome | 27 | 2023 | 32848 | 0.310 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 66 | 0.310 |
Why?
|
Eligibility Determination | 2 | 2019 | 77 | 0.310 |
Why?
|
Lipoproteins | 4 | 2022 | 252 | 0.310 |
Why?
|
Residence Characteristics | 5 | 2016 | 348 | 0.310 |
Why?
|
Drug Costs | 2 | 2019 | 144 | 0.300 |
Why?
|
ROC Curve | 5 | 2012 | 1183 | 0.300 |
Why?
|
Ventricular Function, Left | 3 | 2023 | 603 | 0.300 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 4314 | 0.300 |
Why?
|
Ischemia | 2 | 2020 | 391 | 0.300 |
Why?
|
Intermittent Claudication | 3 | 2023 | 56 | 0.300 |
Why?
|
Femoral Artery | 4 | 2023 | 210 | 0.290 |
Why?
|
Severity of Illness Index | 13 | 2021 | 4320 | 0.290 |
Why?
|
Guideline Adherence | 8 | 2019 | 636 | 0.290 |
Why?
|
Registries | 6 | 2018 | 2170 | 0.290 |
Why?
|
Obesity, Morbid | 3 | 2022 | 224 | 0.280 |
Why?
|
Odds Ratio | 12 | 2019 | 2316 | 0.280 |
Why?
|
Galectins | 3 | 2022 | 71 | 0.280 |
Why?
|
Sex Factors | 6 | 2017 | 2139 | 0.280 |
Why?
|
Apolipoprotein A-I | 2 | 2011 | 84 | 0.280 |
Why?
|
United States Department of Veterans Affairs | 6 | 2021 | 605 | 0.270 |
Why?
|
Inflammation Mediators | 2 | 2020 | 423 | 0.270 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2021 | 340 | 0.270 |
Why?
|
Double-Blind Method | 8 | 2021 | 2588 | 0.270 |
Why?
|
Heart Septum | 1 | 2005 | 54 | 0.270 |
Why?
|
Solvents | 1 | 2005 | 66 | 0.270 |
Why?
|
Heart Ventricles | 3 | 2021 | 846 | 0.270 |
Why?
|
Hypertension, Pulmonary | 2 | 2021 | 462 | 0.260 |
Why?
|
Practice Patterns, Physicians' | 4 | 2018 | 1303 | 0.260 |
Why?
|
Phantoms, Imaging | 1 | 2011 | 1271 | 0.260 |
Why?
|
Lipoproteins, HDL | 1 | 2005 | 144 | 0.260 |
Why?
|
Echocardiography, Stress | 2 | 2020 | 24 | 0.250 |
Why?
|
Protective Factors | 3 | 2021 | 106 | 0.250 |
Why?
|
Waist Circumference | 2 | 2014 | 92 | 0.250 |
Why?
|
Comorbidity | 6 | 2023 | 2352 | 0.230 |
Why?
|
Aged, 80 and over | 22 | 2023 | 29902 | 0.230 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2005 | 192 | 0.230 |
Why?
|
Cardiologists | 1 | 2023 | 33 | 0.230 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2005 | 314 | 0.230 |
Why?
|
Ethanol | 1 | 2005 | 264 | 0.230 |
Why?
|
Clinical Decision-Making | 4 | 2021 | 524 | 0.220 |
Why?
|
Stroke Volume | 3 | 2023 | 577 | 0.220 |
Why?
|
Cognition | 2 | 2019 | 968 | 0.220 |
Why?
|
Thromboembolism | 1 | 2004 | 155 | 0.220 |
Why?
|
Simvastatin | 4 | 2015 | 106 | 0.220 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2023 | 256 | 0.220 |
Why?
|
Calcinosis | 3 | 2014 | 423 | 0.220 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2022 | 13 | 0.210 |
Why?
|
Genome-Wide Association Study | 6 | 2013 | 2265 | 0.210 |
Why?
|
Cardiovascular System | 1 | 2024 | 145 | 0.210 |
Why?
|
Confidence Intervals | 4 | 2017 | 756 | 0.210 |
Why?
|
Blood Volume | 2 | 2020 | 100 | 0.210 |
Why?
|
Hypotension | 1 | 2024 | 210 | 0.210 |
Why?
|
Life Style | 4 | 2021 | 612 | 0.210 |
Why?
|
Thiazolidinediones | 1 | 2002 | 148 | 0.210 |
Why?
|
Thrombolytic Therapy | 1 | 2004 | 257 | 0.200 |
Why?
|
Obesity, Metabolically Benign | 1 | 2021 | 3 | 0.200 |
Why?
|
Retrospective Studies | 21 | 2023 | 37905 | 0.200 |
Why?
|
Heart | 3 | 2024 | 1223 | 0.200 |
Why?
|
Military Medicine | 1 | 2021 | 53 | 0.200 |
Why?
|
Healthcare Disparities | 2 | 2017 | 598 | 0.190 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 2020 | 19 | 0.190 |
Why?
|
Apolipoproteins B | 2 | 2019 | 106 | 0.190 |
Why?
|
Receptors, LDL | 1 | 2021 | 109 | 0.190 |
Why?
|
Education, Medical, Graduate | 2 | 2018 | 671 | 0.190 |
Why?
|
Fish Oils | 1 | 2021 | 88 | 0.190 |
Why?
|
Albuminuria | 2 | 2022 | 113 | 0.190 |
Why?
|
Forecasting | 2 | 2018 | 694 | 0.190 |
Why?
|
Thigh | 3 | 2022 | 172 | 0.190 |
Why?
|
Linear Models | 6 | 2017 | 1085 | 0.190 |
Why?
|
Venous Thrombosis | 1 | 2004 | 384 | 0.180 |
Why?
|
Renin-Angiotensin System | 1 | 2021 | 103 | 0.180 |
Why?
|
Shock, Septic | 1 | 2022 | 181 | 0.180 |
Why?
|
Natriuretic Peptides | 1 | 2019 | 11 | 0.180 |
Why?
|
Clinical Trials as Topic | 7 | 2019 | 3719 | 0.180 |
Why?
|
Pancreatitis | 1 | 2022 | 267 | 0.180 |
Why?
|
Muscle, Skeletal | 4 | 2023 | 1270 | 0.180 |
Why?
|
Regional Blood Flow | 1 | 2020 | 276 | 0.180 |
Why?
|
Vaping | 1 | 2020 | 33 | 0.180 |
Why?
|
Artificial Intelligence | 2 | 2020 | 388 | 0.180 |
Why?
|
Data Collection | 1 | 2022 | 620 | 0.180 |
Why?
|
Surveys and Questionnaires | 6 | 2019 | 5687 | 0.180 |
Why?
|
Perfusion | 2 | 2023 | 293 | 0.180 |
Why?
|
Electronic Nicotine Delivery Systems | 1 | 2020 | 63 | 0.170 |
Why?
|
Retinal Vessels | 1 | 2020 | 85 | 0.170 |
Why?
|
Patient Care Management | 1 | 2020 | 94 | 0.170 |
Why?
|
India | 1 | 2020 | 301 | 0.170 |
Why?
|
P-Selectin | 2 | 2010 | 124 | 0.170 |
Why?
|
Consensus | 2 | 2021 | 978 | 0.170 |
Why?
|
ATP Binding Cassette Transporter 1 | 1 | 2018 | 29 | 0.170 |
Why?
|
Tobacco Products | 1 | 2020 | 120 | 0.170 |
Why?
|
Cerebrovascular Disorders | 2 | 2018 | 142 | 0.170 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2016 | 1209 | 0.170 |
Why?
|
Age Factors | 7 | 2020 | 5377 | 0.170 |
Why?
|
Blood Flow Velocity | 1 | 2020 | 475 | 0.170 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2019 | 136 | 0.170 |
Why?
|
Venous Thromboembolism | 2 | 2014 | 335 | 0.170 |
Why?
|
Microvessels | 1 | 2020 | 135 | 0.170 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2019 | 119 | 0.170 |
Why?
|
Renal Replacement Therapy | 1 | 2020 | 135 | 0.160 |
Why?
|
Drug Prescriptions | 3 | 2018 | 289 | 0.160 |
Why?
|
Machine Learning | 1 | 2021 | 319 | 0.160 |
Why?
|
Walking | 1 | 2020 | 277 | 0.160 |
Why?
|
Sick Sinus Syndrome | 1 | 2018 | 14 | 0.160 |
Why?
|
Renal Insufficiency | 3 | 2011 | 321 | 0.160 |
Why?
|
Behavior Therapy | 1 | 2021 | 298 | 0.160 |
Why?
|
Veterans Health | 2 | 2019 | 181 | 0.160 |
Why?
|
Eicosapentaenoic Acid | 1 | 2019 | 92 | 0.160 |
Why?
|
Death, Sudden, Cardiac | 1 | 2020 | 253 | 0.160 |
Why?
|
Apolipoprotein C-III | 2 | 2022 | 31 | 0.160 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2012 | 257 | 0.160 |
Why?
|
Contrast Media | 4 | 2019 | 1472 | 0.160 |
Why?
|
Genetic Predisposition to Disease | 8 | 2023 | 5539 | 0.160 |
Why?
|
Endarterectomy, Carotid | 2 | 2015 | 121 | 0.160 |
Why?
|
Hypogonadism | 1 | 2021 | 257 | 0.150 |
Why?
|
Vena Cava, Superior | 1 | 2018 | 78 | 0.150 |
Why?
|
Apolipoproteins E | 1 | 2018 | 221 | 0.150 |
Why?
|
Hospital Mortality | 5 | 2022 | 1274 | 0.150 |
Why?
|
Biological Transport | 1 | 2018 | 597 | 0.150 |
Why?
|
Benchmarking | 1 | 2019 | 273 | 0.150 |
Why?
|
Phospholipases A2 | 2 | 2007 | 43 | 0.150 |
Why?
|
Preoperative Care | 4 | 2012 | 1529 | 0.150 |
Why?
|
Attitude of Health Personnel | 2 | 2016 | 918 | 0.150 |
Why?
|
Risk | 5 | 2014 | 1972 | 0.150 |
Why?
|
Exercise Therapy | 3 | 2021 | 288 | 0.150 |
Why?
|
Glomerular Filtration Rate | 4 | 2022 | 602 | 0.150 |
Why?
|
Myocardial Revascularization | 3 | 2021 | 134 | 0.140 |
Why?
|
Logistic Models | 9 | 2016 | 3441 | 0.140 |
Why?
|
Mortality | 2 | 2024 | 343 | 0.140 |
Why?
|
Patient Selection | 3 | 2019 | 2055 | 0.140 |
Why?
|
Monitoring, Physiologic | 1 | 2019 | 502 | 0.140 |
Why?
|
Cystatin C | 1 | 2016 | 54 | 0.140 |
Why?
|
Femoral Vein | 1 | 2016 | 66 | 0.140 |
Why?
|
Heart Transplantation | 1 | 2023 | 908 | 0.140 |
Why?
|
Alcohol Dehydrogenase | 1 | 2016 | 33 | 0.140 |
Why?
|
Education, Medical, Continuing | 2 | 2016 | 251 | 0.140 |
Why?
|
Testosterone | 1 | 2021 | 619 | 0.140 |
Why?
|
Serine Endopeptidases | 1 | 2017 | 275 | 0.140 |
Why?
|
Treatment Failure | 2 | 2018 | 1391 | 0.140 |
Why?
|
Cell-Derived Microparticles | 1 | 2016 | 41 | 0.140 |
Why?
|
Decision Support Techniques | 2 | 2019 | 622 | 0.140 |
Why?
|
Antibodies, Monoclonal | 2 | 2020 | 4367 | 0.130 |
Why?
|
Metabolomics | 1 | 2019 | 478 | 0.130 |
Why?
|
Postoperative Care | 1 | 2019 | 739 | 0.130 |
Why?
|
Inservice Training | 1 | 2016 | 78 | 0.130 |
Why?
|
Blood Proteins | 3 | 2022 | 294 | 0.130 |
Why?
|
Young Adult | 5 | 2023 | 21445 | 0.130 |
Why?
|
Oxygen | 1 | 2019 | 754 | 0.130 |
Why?
|
Fenofibrate | 2 | 2013 | 57 | 0.130 |
Why?
|
Pacemaker, Artificial | 1 | 2018 | 213 | 0.130 |
Why?
|
Physicians | 1 | 2023 | 882 | 0.130 |
Why?
|
Endpoint Determination | 2 | 2007 | 176 | 0.130 |
Why?
|
Amino Acids | 1 | 2018 | 728 | 0.130 |
Why?
|
RNA, Small Interfering | 1 | 2021 | 2216 | 0.130 |
Why?
|
Texas | 8 | 2019 | 6311 | 0.130 |
Why?
|
Healthy Volunteers | 1 | 2015 | 187 | 0.130 |
Why?
|
Longitudinal Studies | 5 | 2020 | 1945 | 0.130 |
Why?
|
Endothelium, Vascular | 3 | 2013 | 891 | 0.130 |
Why?
|
Lower Extremity | 2 | 2022 | 299 | 0.120 |
Why?
|
Postoperative Complications | 5 | 2012 | 5542 | 0.120 |
Why?
|
Diabetes Complications | 1 | 2016 | 305 | 0.120 |
Why?
|
Chemokine CCL5 | 2 | 2013 | 71 | 0.120 |
Why?
|
Medication Adherence | 1 | 2019 | 492 | 0.120 |
Why?
|
Fibrinolytic Agents | 3 | 2020 | 324 | 0.120 |
Why?
|
Fellowships and Scholarships | 1 | 2018 | 390 | 0.120 |
Why?
|
Smoking Cessation | 1 | 2020 | 712 | 0.120 |
Why?
|
Internship and Residency | 2 | 2018 | 1375 | 0.120 |
Why?
|
Occupations | 1 | 2014 | 50 | 0.120 |
Why?
|
Heptanoic Acids | 3 | 2014 | 96 | 0.120 |
Why?
|
Cognitive Dysfunction | 1 | 2019 | 333 | 0.120 |
Why?
|
Smoking | 3 | 2023 | 2440 | 0.120 |
Why?
|
Propensity Score | 3 | 2012 | 750 | 0.120 |
Why?
|
Athletes | 1 | 2014 | 73 | 0.120 |
Why?
|
Heart-Assist Devices | 1 | 2023 | 1171 | 0.120 |
Why?
|
Ceruloplasmin | 1 | 2013 | 35 | 0.120 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2013 | 42 | 0.120 |
Why?
|
Ambulatory Care Facilities | 1 | 2016 | 289 | 0.120 |
Why?
|
Acetates | 1 | 2014 | 105 | 0.120 |
Why?
|
Delivery of Health Care | 1 | 2020 | 860 | 0.120 |
Why?
|
Drug Therapy, Combination | 5 | 2021 | 2315 | 0.120 |
Why?
|
Prescription Drugs | 1 | 2014 | 64 | 0.110 |
Why?
|
Health Status | 1 | 2016 | 590 | 0.110 |
Why?
|
Brain Infarction | 1 | 2013 | 31 | 0.110 |
Why?
|
Thiophenes | 1 | 2014 | 148 | 0.110 |
Why?
|
Fibrosis | 3 | 2022 | 793 | 0.110 |
Why?
|
Hyperglycemia | 2 | 2013 | 333 | 0.110 |
Why?
|
Diet Therapy | 1 | 2013 | 52 | 0.110 |
Why?
|
Global Health | 1 | 2018 | 657 | 0.110 |
Why?
|
Leukoencephalopathies | 1 | 2013 | 63 | 0.110 |
Why?
|
Adenosine Diphosphate | 2 | 2011 | 113 | 0.110 |
Why?
|
Alcohol Drinking | 1 | 2016 | 551 | 0.110 |
Why?
|
Curriculum | 1 | 2018 | 860 | 0.110 |
Why?
|
Arachidonic Acid | 2 | 2011 | 118 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6207 | 0.110 |
Why?
|
Mammography | 1 | 2018 | 1010 | 0.110 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2009 | 563 | 0.110 |
Why?
|
Transcription Factor 7-Like 2 Protein | 1 | 2012 | 41 | 0.100 |
Why?
|
Heart Valves | 2 | 2010 | 66 | 0.100 |
Why?
|
Pilot Projects | 2 | 2016 | 2803 | 0.100 |
Why?
|
Up-Regulation | 4 | 2020 | 2450 | 0.100 |
Why?
|
Death | 1 | 2012 | 119 | 0.100 |
Why?
|
Lipoproteins, LDL | 1 | 2012 | 163 | 0.100 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2020 | 3251 | 0.100 |
Why?
|
Pandemics | 1 | 2020 | 1559 | 0.100 |
Why?
|
Liver | 1 | 2021 | 2961 | 0.100 |
Why?
|
Neck | 1 | 2014 | 383 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2013 | 317 | 0.100 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 1085 | 0.100 |
Why?
|
Platelet Function Tests | 1 | 2011 | 50 | 0.100 |
Why?
|
Vasodilator Agents | 2 | 2022 | 219 | 0.100 |
Why?
|
Multivariate Analysis | 5 | 2021 | 4298 | 0.100 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2011 | 108 | 0.100 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 254 | 0.100 |
Why?
|
Pravastatin | 2 | 2008 | 34 | 0.100 |
Why?
|
Vasculitis | 1 | 2011 | 61 | 0.100 |
Why?
|
Area Under Curve | 2 | 2012 | 700 | 0.090 |
Why?
|
Pyrroles | 3 | 2014 | 576 | 0.090 |
Why?
|
Behavioral Risk Factor Surveillance System | 2 | 2020 | 60 | 0.090 |
Why?
|
Muscles | 1 | 2011 | 416 | 0.090 |
Why?
|
Phenotype | 7 | 2020 | 6295 | 0.090 |
Why?
|
Down-Regulation | 1 | 2015 | 2074 | 0.090 |
Why?
|
Reference Values | 4 | 2017 | 1099 | 0.090 |
Why?
|
Early Diagnosis | 1 | 2011 | 298 | 0.090 |
Why?
|
Endothelial Cells | 1 | 2016 | 1048 | 0.090 |
Why?
|
Cardiac Surgical Procedures | 2 | 2010 | 1237 | 0.090 |
Why?
|
Apolipoproteins A | 1 | 2009 | 42 | 0.090 |
Why?
|
ABO Blood-Group System | 1 | 2010 | 127 | 0.090 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2010 | 221 | 0.090 |
Why?
|
Cost-Benefit Analysis | 2 | 2019 | 945 | 0.090 |
Why?
|
Societies, Medical | 1 | 2015 | 1335 | 0.090 |
Why?
|
Drug Monitoring | 2 | 2021 | 333 | 0.090 |
Why?
|
Sex Characteristics | 1 | 2012 | 417 | 0.080 |
Why?
|
Genetic Testing | 2 | 2022 | 1589 | 0.080 |
Why?
|
Niacin | 3 | 2013 | 61 | 0.080 |
Why?
|
Prasugrel Hydrochloride | 2 | 2021 | 25 | 0.080 |
Why?
|
Algorithms | 4 | 2016 | 3890 | 0.080 |
Why?
|
Stress, Mechanical | 1 | 2009 | 311 | 0.080 |
Why?
|
HIV-1 | 1 | 2013 | 653 | 0.080 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2014 | 1648 | 0.080 |
Why?
|
Epinephrine | 1 | 2009 | 255 | 0.080 |
Why?
|
Indoles | 1 | 2014 | 1009 | 0.080 |
Why?
|
Models, Genetic | 1 | 2012 | 1113 | 0.080 |
Why?
|
Weight Loss | 2 | 2021 | 627 | 0.080 |
Why?
|
Case-Control Studies | 3 | 2016 | 6100 | 0.070 |
Why?
|
Netherlands | 2 | 2020 | 83 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2008 | 435 | 0.070 |
Why?
|
In Vitro Techniques | 1 | 2009 | 1618 | 0.070 |
Why?
|
Arterial Occlusive Diseases | 1 | 2007 | 160 | 0.070 |
Why?
|
Aging | 3 | 2022 | 1582 | 0.070 |
Why?
|
Molecular Biology | 1 | 2007 | 176 | 0.070 |
Why?
|
Collagen | 1 | 2009 | 752 | 0.070 |
Why?
|
Gadolinium DTPA | 2 | 2019 | 172 | 0.070 |
Why?
|
Patient Discharge | 2 | 2022 | 661 | 0.070 |
Why?
|
Combined Modality Therapy | 3 | 2021 | 8865 | 0.060 |
Why?
|
Piperazines | 1 | 2014 | 2101 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2021 | 4938 | 0.060 |
Why?
|
DNA | 1 | 2013 | 2693 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 1489 | 0.060 |
Why?
|
Mass Screening | 2 | 2014 | 1509 | 0.060 |
Why?
|
Electrocardiography | 2 | 2021 | 1145 | 0.060 |
Why?
|
Acute Disease | 2 | 2022 | 2422 | 0.060 |
Why?
|
Echocardiography, Doppler | 1 | 2005 | 180 | 0.060 |
Why?
|
Mutation | 1 | 2004 | 15179 | 0.060 |
Why?
|
Lipid Peroxidation | 1 | 2005 | 157 | 0.060 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 305 | 0.060 |
Why?
|
Angioplasty | 1 | 2004 | 94 | 0.060 |
Why?
|
Anthropometry | 2 | 2014 | 269 | 0.060 |
Why?
|
Mitral Valve | 1 | 2005 | 271 | 0.060 |
Why?
|
Electrophysiologic Techniques, Cardiac | 1 | 2003 | 69 | 0.060 |
Why?
|
Inpatients | 1 | 2009 | 678 | 0.060 |
Why?
|
Interleukin-18 | 1 | 2023 | 100 | 0.060 |
Why?
|
Ventricular Fibrillation | 1 | 2003 | 61 | 0.060 |
Why?
|
Cardiovascular Agents | 1 | 2004 | 128 | 0.060 |
Why?
|
Genotype | 4 | 2013 | 4109 | 0.060 |
Why?
|
Asymptomatic Diseases | 2 | 2014 | 100 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2006 | 461 | 0.050 |
Why?
|
Brachial Artery | 1 | 2022 | 38 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2010 | 1162 | 0.050 |
Why?
|
Chest Pain | 1 | 2003 | 155 | 0.050 |
Why?
|
Angiopoietin-like Proteins | 1 | 2022 | 14 | 0.050 |
Why?
|
Hyperinsulinism | 1 | 2002 | 85 | 0.050 |
Why?
|
Dyspnea | 1 | 2005 | 416 | 0.050 |
Why?
|
Internationality | 1 | 2023 | 208 | 0.050 |
Why?
|
Azetidines | 2 | 2013 | 87 | 0.050 |
Why?
|
United States Department of Defense | 1 | 2021 | 9 | 0.050 |
Why?
|
Social Class | 1 | 2023 | 310 | 0.050 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 1450 | 0.050 |
Why?
|
Survival Rate | 4 | 2017 | 12221 | 0.050 |
Why?
|
Public Health | 1 | 2024 | 299 | 0.050 |
Why?
|
Coronary Angiography | 2 | 2014 | 598 | 0.050 |
Why?
|
Heart Valve Prosthesis | 1 | 2005 | 386 | 0.050 |
Why?
|
Minority Groups | 1 | 2023 | 322 | 0.050 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 1323 | 0.050 |
Why?
|
Ultrasonics | 1 | 2020 | 69 | 0.050 |
Why?
|
Frail Elderly | 1 | 2021 | 118 | 0.050 |
Why?
|
Weight Reduction Programs | 1 | 2021 | 78 | 0.050 |
Why?
|
Hospitals | 1 | 2023 | 485 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 1879 | 0.040 |
Why?
|
Extracellular Space | 1 | 2019 | 132 | 0.040 |
Why?
|
Proteomics | 1 | 2007 | 1380 | 0.040 |
Why?
|
Alleles | 3 | 2011 | 2437 | 0.040 |
Why?
|
Syndrome | 1 | 2023 | 1351 | 0.040 |
Why?
|
Research Design | 1 | 2007 | 1544 | 0.040 |
Why?
|
Exercise Test | 1 | 2020 | 312 | 0.040 |
Why?
|
Apolipoprotein E4 | 1 | 2019 | 48 | 0.040 |
Why?
|
Gene Frequency | 2 | 2012 | 1163 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2023 | 1038 | 0.040 |
Why?
|
Postmenopause | 1 | 2020 | 378 | 0.040 |
Why?
|
Hormone Replacement Therapy | 1 | 2021 | 205 | 0.040 |
Why?
|
Metformin | 1 | 2002 | 378 | 0.040 |
Why?
|
Models, Economic | 1 | 2019 | 101 | 0.040 |
Why?
|
Motor Activity | 1 | 2002 | 693 | 0.040 |
Why?
|
Quality of Life | 2 | 2022 | 4532 | 0.040 |
Why?
|
Patient Compliance | 1 | 2002 | 667 | 0.040 |
Why?
|
Thiazoles | 1 | 2002 | 726 | 0.040 |
Why?
|
Hypoglycemic Agents | 1 | 2002 | 586 | 0.040 |
Why?
|
Surgical Wound Infection | 2 | 2012 | 450 | 0.040 |
Why?
|
Observer Variation | 2 | 2014 | 671 | 0.040 |
Why?
|
Bone Density | 1 | 2021 | 476 | 0.040 |
Why?
|
Hospitals, Veterans | 1 | 2020 | 397 | 0.040 |
Why?
|
Myocardial Ischemia | 1 | 2021 | 435 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 543 | 0.040 |
Why?
|
Administration, Oral | 1 | 2021 | 1544 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 1225 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2021 | 558 | 0.040 |
Why?
|
Adolescent | 3 | 2023 | 31252 | 0.040 |
Why?
|
Patient Readmission | 1 | 2021 | 548 | 0.040 |
Why?
|
Walk Test | 1 | 2016 | 43 | 0.040 |
Why?
|
Memory, Episodic | 1 | 2016 | 32 | 0.040 |
Why?
|
Overweight | 1 | 2020 | 484 | 0.040 |
Why?
|
Extracellular Matrix | 1 | 2019 | 554 | 0.040 |
Why?
|
Medicare | 1 | 2021 | 860 | 0.030 |
Why?
|
Hyperemia | 1 | 2016 | 40 | 0.030 |
Why?
|
Genomics | 1 | 2007 | 2738 | 0.030 |
Why?
|
Models, Statistical | 2 | 2013 | 1171 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2017 | 306 | 0.030 |
Why?
|
Cause of Death | 1 | 2019 | 752 | 0.030 |
Why?
|
Limit of Detection | 1 | 2015 | 78 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2018 | 462 | 0.030 |
Why?
|
Drug Utilization | 1 | 2016 | 179 | 0.030 |
Why?
|
Independent Living | 1 | 2015 | 73 | 0.030 |
Why?
|
Precision Medicine | 1 | 2022 | 1154 | 0.030 |
Why?
|
Critical Illness | 1 | 2020 | 714 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2019 | 1178 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2015 | 2594 | 0.030 |
Why?
|
Phospholipases A2, Secretory | 1 | 2014 | 3 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2014 | 114 | 0.030 |
Why?
|
Recurrence | 2 | 2013 | 4758 | 0.030 |
Why?
|
Blood Glucose | 1 | 2018 | 1244 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2014 | 85 | 0.030 |
Why?
|
Keto Acids | 1 | 2014 | 59 | 0.030 |
Why?
|
Angina, Unstable | 1 | 2014 | 70 | 0.030 |
Why?
|
X-Ray Microtomography | 1 | 2014 | 141 | 0.030 |
Why?
|
Blood Chemical Analysis | 1 | 2014 | 118 | 0.030 |
Why?
|
Diabetic Angiopathies | 1 | 2013 | 78 | 0.030 |
Why?
|
Multidetector Computed Tomography | 1 | 2014 | 150 | 0.030 |
Why?
|
Estrogen Replacement Therapy | 1 | 2013 | 105 | 0.030 |
Why?
|
Biological Assay | 1 | 2014 | 177 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2013 | 3472 | 0.030 |
Why?
|
Respiration Disorders | 1 | 2012 | 45 | 0.030 |
Why?
|
Elastic Modulus | 1 | 2012 | 37 | 0.030 |
Why?
|
Exome | 1 | 2018 | 1239 | 0.030 |
Why?
|
Heart Injuries | 1 | 2012 | 40 | 0.030 |
Why?
|
Discriminant Analysis | 1 | 2012 | 48 | 0.030 |
Why?
|
Cytochrome P-450 CYP2B6 | 1 | 2012 | 22 | 0.030 |
Why?
|
HapMap Project | 1 | 2011 | 19 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2011 | 72 | 0.030 |
Why?
|
Renal Dialysis | 2 | 2010 | 945 | 0.030 |
Why?
|
Oxidoreductases, N-Demethylating | 1 | 2012 | 41 | 0.030 |
Why?
|
Lipoprotein Lipase | 1 | 2012 | 52 | 0.030 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 78 | 0.030 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2013 | 311 | 0.030 |
Why?
|
Normal Distribution | 1 | 2011 | 61 | 0.030 |
Why?
|
Gene-Environment Interaction | 1 | 2012 | 166 | 0.030 |
Why?
|
Nuclear Receptor Coactivator 2 | 1 | 2012 | 210 | 0.020 |
Why?
|
Placebo Effect | 1 | 2011 | 39 | 0.020 |
Why?
|
Automation | 1 | 2011 | 151 | 0.020 |
Why?
|
Family Practice | 1 | 2011 | 125 | 0.020 |
Why?
|
Pattern Recognition, Automated | 1 | 2011 | 125 | 0.020 |
Why?
|
Internal Medicine | 1 | 2011 | 124 | 0.020 |
Why?
|
Blood Specimen Collection | 1 | 2011 | 93 | 0.020 |
Why?
|
Anticoagulants | 1 | 2016 | 787 | 0.020 |
Why?
|
Disease-Free Survival | 2 | 2013 | 10001 | 0.020 |
Why?
|
Morbidity | 1 | 2012 | 397 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2014 | 1363 | 0.020 |
Why?
|
Postoperative Period | 1 | 2012 | 665 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2011 | 430 | 0.020 |
Why?
|
Primary Health Care | 1 | 2016 | 787 | 0.020 |
Why?
|
Health Services Research | 1 | 2011 | 233 | 0.020 |
Why?
|
Necrosis | 1 | 2011 | 580 | 0.020 |
Why?
|
Magnetic Resonance Angiography | 1 | 2010 | 216 | 0.020 |
Why?
|
Postoperative Hemorrhage | 1 | 2011 | 162 | 0.020 |
Why?
|
Fluorescence | 1 | 2010 | 195 | 0.020 |
Why?
|
Temperature | 1 | 2011 | 506 | 0.020 |
Why?
|
Angioplasty, Balloon | 1 | 2011 | 183 | 0.020 |
Why?
|
Haplotypes | 1 | 2012 | 856 | 0.020 |
Why?
|
Endocrinology | 1 | 2011 | 139 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 3033 | 0.020 |
Why?
|
Drug Resistance | 1 | 2011 | 587 | 0.020 |
Why?
|
Genetic Loci | 1 | 2011 | 481 | 0.020 |
Why?
|
Community-Based Participatory Research | 1 | 2009 | 56 | 0.020 |
Why?
|
Databases, Factual | 1 | 2016 | 2218 | 0.020 |
Why?
|
Hemodynamics | 1 | 2012 | 935 | 0.020 |
Why?
|
Regression Analysis | 1 | 2012 | 1546 | 0.020 |
Why?
|
Survival Analysis | 2 | 2014 | 9180 | 0.020 |
Why?
|
Brain Mapping | 1 | 2011 | 644 | 0.020 |
Why?
|
Respiratory Insufficiency | 1 | 2011 | 330 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2016 | 5637 | 0.020 |
Why?
|
Sepsis | 1 | 2012 | 652 | 0.020 |
Why?
|
Pneumonia | 1 | 2012 | 751 | 0.020 |
Why?
|
Heart Valve Diseases | 1 | 2007 | 193 | 0.020 |
Why?
|
Perioperative Care | 1 | 2010 | 451 | 0.020 |
Why?
|
Blood Platelets | 1 | 2010 | 731 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2007 | 323 | 0.020 |
Why?
|
Stents | 1 | 2011 | 1096 | 0.020 |
Why?
|
Creatine Kinase, MB Form | 1 | 2003 | 29 | 0.010 |
Why?
|
Creatine Kinase | 1 | 2003 | 92 | 0.010 |
Why?
|
Coronary Thrombosis | 1 | 2003 | 44 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 7548 | 0.010 |
Why?
|
Genome, Human | 1 | 2011 | 1869 | 0.010 |
Why?
|
Length of Stay | 1 | 2009 | 1900 | 0.010 |
Why?
|
Isoenzymes | 1 | 2003 | 614 | 0.010 |
Why?
|
Probability | 1 | 2002 | 866 | 0.010 |
Why?
|
Defibrillators, Implantable | 1 | 2003 | 221 | 0.010 |
Why?
|
Animals | 1 | 2005 | 59536 | 0.010 |
Why?
|
Brain | 1 | 2011 | 4113 | 0.010 |
Why?
|
Disease Progression | 1 | 2007 | 6682 | 0.010 |
Why?
|
Neoplasms | 1 | 2012 | 15193 | 0.000 |
Why?
|